Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.

ABSTRACT:

Objectives

Infections due to carbapenem-resistant Enterobacterales are considered urgent public health threats and often treated with a β-lactam/β-lactamase inhibitor combination. However, clinical treatment failure and resistance emergence have been attributed to inadequate dosing. We used a novel framework to provide insights of optimal dosing exposure of ceftazidime/avibactam.

Methods

Seven clinical isolates of Klebsiella pneumoniae producing different KPC variants were examined. Ceftazidime susceptibility (MIC) was determined by broth dilution using escalating concentrations of avibactam. The observed MICs were characterized as response to avibactam concentrations using an inhibitory sigmoid Emax model. Using the best-fit parameter values, %fT>MICi was estimated for v

SUBMITTER: Tam VH 

PROVIDER: S-EPMC10205629 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature